Two Onc Docs

This podcast discusses acquired forms of hemolytic anemia, such as warm autoimmune hemolytic anemia, cold agglutinin disease, and paroxysmal cold hemoglobinuria. They explore various types of hemolytic anemia, treatment options, key toxicities of monoclonal antibodies, and important takeaways for distinguishing and treating different types of hemolytic anemia.

This week’s episode will be focusing on inherited platelet disorders. We will go over the important details on the roles of platelets, the  diagnosis of inherited platelet disorders through aggregation studies, as well as the treatment of these disorders.

Discussion on primary myelofibrosis (PMF) and other myeloproliferative neoplasms, including diagnosis, risk stratification, treatment options. Topics include extra-medular hematopoiesis, diagnostic criteria, staging, risk factors, molecular risk, prognosis, supportive care, medication options, stem cell transplant.

Exploring risk factors, diagnosis, and treatment strategies for esophageal cancer. Detailed overview of localized cancer treatment and radiation effects. Discussing different dissection types and various treatment options for metastatic cases.

This week’s episode will be focusing on another one of the myeloproliferative neoplasms (MPN): Polycythemia Vera (PV). We will go over the important details on the diagnosis, risk stratification, and treatment.

This podcast dives into the world of Bone Sarcomas, covering topics such as diagnosis, staging, and treatment strategies for osteosarcomas, Ewing sarcomas, and chondrosarcomas. It discusses the rarity of bone sarcomas, the importance of expert biopsies, intensive chemotherapy regimens, limb-sparing surgery considerations, and the challenges of treating resistant chondrocercomas.

The podcast discusses the diagnosis, subtypes, and treatment of soft tissue sarcomas. It explores the molecular abnormalities associated with sarcomas and highlights common misdiagnosis. The importance of accurate pathology, staging, and prognostic factors for sarcomas is also covered. Treatment options for localized and metastatic sarcomas are discussed, including surgery, radiation, and targeted therapies. An overview of Kaposi's sarcoma and key takeaways on sarcoma treatment are provided.

This podcast discusses the management of ER positive HER2 negative breast cancer, including the NATALEE Trial on adding ribocyclib to endocrine therapy. They explore the use of CDK46 inhibitor, compare ribocyclib with aromatase inhibitor alone, and analyze its impact on localized breast cancer treatment. The episode also focuses on optimizing clinical trial design for reliable results and stresses the importance of further research on overall survival data.

Exploring frontline and second-line treatment options for metastatic RCC including combinations of tyrosine kinase inhibitors and immunotherapy agents based on risk criteria. Analysis of the CONTACT03 Trial outcomes revealing no significant difference between PDL-1 monoclonal antibody with cabozantinib compared to cabozantinib alone. Insights on response rates, challenges in subgroup analysis, and toxicity profile in metastatic RCC patients post-progressing on prior treatment. Discussion on negative study results, subgroup analysis complexities, and impact on treatment paradigms in oncology trials.

Join us for a recap on the treatment of rectal cancer, including a discussion on the PROSPECT Trial at ASCO 2023. Delve into the nuances of total neoadjuvant therapy, selective chemo radiation, non-inferiority trial design, and patient outcomes in rectal cancer treatment.